Last updated: 2 March 2023 at 4:48pm EST

Jason Duncan Net Worth




The estimated Net Worth of Jason Duncan is at least $1.06 Million dollars as of 23 January 2023. Mr. Duncan owns over 228 units of Albireo Pharma Inc stock worth over $624,546 and over the last 6 years he sold ALBO stock worth over $437,493. In addition, he makes $0 as Chief Legal Officer, General Counsel, and Secretary at Albireo Pharma Inc.

Mr. Duncan ALBO stock SEC Form 4 insiders trading

Jason has made over 17 trades of the Albireo Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 228 units of ALBO stock worth $9,986 on 23 January 2023.

The largest trade he's ever made was exercising 16,300 units of Albireo Pharma Inc stock on 24 June 2021 worth over $396,416. On average, Jason trades about 1,301 units every 50 days since 2018. As of 23 January 2023 he still owns at least 14,146 units of Albireo Pharma Inc stock.

You can see the complete history of Mr. Duncan stock trades at the bottom of the page.





Jason Duncan biography

Jason G. Duncan serves as Chief Legal Officer, General Counsel, Secretary of the Company. He has served as our Chief Legal Officer since January 2020 and as our General Counsel and Secretary since June 2018. He previously served as General Counsel at Stallergenes Greer Holdings, Inc. from August 2015 to June 2018, where he oversaw all legal activities for the allergy immunotherapy company's Americas business. Previously, from May 2014 to August 2015, Mr. Duncan was Vice President, Head of Compliance and Legal for Sobi, Inc., a global biopharmaceutical company focused on rare inflammatory and genetic diseases. At Sobi, Mr. Duncan was responsible for all legal and compliance matters for the company's North American affiliates, and served on the leadership team. Prior to Sobi, from December 2006 to May 2014, Mr. Duncan held roles of increasing responsibility at EMD Serono, Inc., culminating in his position as Associate General Counsel for Neurology and Discovery.



How old is Jason Duncan?

Jason Duncan is 46, he's been the Chief Legal Officer, General Counsel, and Secretary of Albireo Pharma Inc since 2020. There are 20 older and no younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.

What's Jason Duncan's mailing address?

Jason's mailing address filed with the SEC is C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON, MA, 02109.

Insiders trading at Albireo Pharma Inc

Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs, and Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.



What does Albireo Pharma Inc do?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.



What does Albireo Pharma Inc's logo look like?

Albireo Pharma Inc logo

Complete history of Mr. Duncan stock trades at Albireo Pharma Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
23 Jan 2023 Jason Duncan
Chief Legal Officer and GC
Sale 228 $43.80 $9,986
23 Jan 2023
14,146
19 Jan 2023 Jason Duncan
Chief Legal Officer and GC
Sale 938 $43.90 $41,178
19 Jan 2023
14,374
24 Oct 2022 Jason Duncan
Chief Legal Officer and GC
Sale 656 $19.45 $12,759
24 Oct 2022
14,931
22 Jul 2022 Jason Duncan
Chief Legal Officer and GC
Sale 657 $24.21 $15,906
22 Jul 2022
15,587
22 Apr 2022 Jason Duncan
Chief Legal Officer and GC
Sale 655 $33.22 $21,759
22 Apr 2022
16,008
24 Jan 2022 Jason Duncan
Chief Legal Officer and GC
Sale 1,688 $24.94 $42,099
24 Jan 2022
16,663
22 Oct 2021 Jason Duncan
Chief Legal Officer and GC
Sale 312 $29.10 $9,079
22 Oct 2021
7,355
22 Jul 2021 Jason Duncan
Chief Legal Officer and GC
Sale 313 $32.21 $10,082
22 Jul 2021
7,667
24 Jun 2021 Jason Duncan
Chief Legal Officer and GC
Option 16,300 $24.32 $396,416
24 Jun 2021
14,280
22 Apr 2021 Jason Duncan
Chief Legal Officer and GC
Sale 312 $32.16 $10,034
22 Apr 2021
7,849
31 Mar 2021 Jason Duncan
Chief Legal Officer and GC
Sale 1,726 $35.24 $60,824
31 Mar 2021
8,161
21 Jan 2021 Jason Duncan
Chief Legal Officer and GC
Sale 110 $34.62 $3,808
21 Jan 2021
9,332
22 Oct 2020 Jason Duncan
Chief Legal Officer and GC
Sale 89 $34.71 $3,089
22 Oct 2020
3,781
8 Sep 2020 Jason Duncan
Chief Legal Officer and GC
Sale 4,000 $45.55 $182,200
8 Sep 2020
3,870
22 Jul 2020 Jason Duncan
Chief Legal Officer and GC
Sale 91 $25.80 $2,348
22 Jul 2020
4,370
22 Apr 2020 Jason Duncan
Chief Legal Officer and GC
Sale 92 $17.68 $1,627
22 Apr 2020
4,461
21 Jan 2020 Jason Duncan
Chief Legal Officer and GC
Sale 447 $23.97 $10,715
21 Jan 2020
4,553


Albireo Pharma Inc executives and stock owners

Albireo Pharma Inc executives and other stock owners filed with the SEC include: